Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)

Peter H. Jones , Michael H. Davidson , Evan A. Stein , Peter H. Jones , Michael H. Davidson , Evan A. Stein , Harold Bays , James M. McKenney , Elinor Miller , Valerie A. Cain , James W. Blasetto
2003 The American Journal of Cardiology 1,382 citations

Abstract

The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose ranges for reduction of low-density lipoprotein (LDL) cholesterol. Secondary objectives included comparing rosuvastatin with comparators for other lipid modifications and achievement of National Cholesterol Education Program Adult Treatment Panel III and Joint European Task Force LDL cholesterol goals. After a dietary lead-in period, 2,431 adults with hypercholesterolemia (LDL cholesterol > or =160 and <250 mg/dl; triglycerides <400 mg/dl) were randomized to treatment with rosuvastatin 10, 20, 40, or 80 mg; atorvastatin 10, 20, 40, or 80 mg; simvastatin 10, 20, 40, or 80 mg; or pravastatin 10, 20, or 40 mg. At 6 weeks, across-dose analyses showed that rosuvastatin 10 to 80 mg reduced LDL cholesterol by a mean of 8.2% more than atorvastatin 10 to 80 mg, 26% more than pravastatin 10 to 40 mg, and 12% to 18% more than simvastatin 10 to 80 mg (all p <0.001). Mean percent changes in high-density lipoprotein cholesterol in the rosuvastatin groups were +7.7% to +9.6% compared with +2.1% to +6.8% in all other groups. Across dose ranges, rosuvastatin reduced total cholesterol significantly more (p <0.001) than all comparators and triglycerides significantly more (p <0.001) than simvastatin and pravastatin. Adult Treatment Panel III LDL cholesterol goals were achieved by 82% to 89% of patients treated with rosuvastatin 10 to 40 mg compared with 69% to 85% of patients treated with atorvastatin 10 to 80 mg; the European LDL cholesterol goal of <3.0 mmol/L was achieved by 79% to 92% in rosuvastatin groups compared with 52% to 81% in atorvastatin groups. Drug tolerability was similar across treatments.

Keywords

RosuvastatinPravastatinSimvastatinAtorvastatinMedicineStatinHMG-CoA reductaseCholesterolNational Cholesterol Education ProgramRosuvastatin CalciumInternal medicineUrologyEndocrinologyPharmacologyReductaseChemistryBiochemistryEnzymeMetabolic syndrome

MeSH Terms

AdultAgedAged80 and overAtorvastatinCholesterolLDLDose-Response RelationshipDrugFemaleFluorobenzenesHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaMaleMiddle AgedPravastatinPyrimidinesPyrrolesRosuvastatin CalciumSimvastatinSulfonamidesTime Factors

Affiliated Institutions

Related Publications

Publication Info

Year
2003
Type
article
Volume
92
Issue
2
Pages
152-160
Citations
1382
Access
Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1382
OpenAlex
6
Influential
1083
CrossRef

Cite This

Peter H. Jones, Michael H. Davidson, Evan A. Stein et al. (2003). Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial). The American Journal of Cardiology , 92 (2) , 152-160. https://doi.org/10.1016/s0002-9149(03)00530-7

Identifiers

DOI
10.1016/s0002-9149(03)00530-7
PMID
12860216

Data Quality

Data completeness: 86%